Zentalis Pharmaceuticals (NASDAQ:ZNTL) Given New $6.00 Price Target at Wells Fargo & Company

Zentalis Pharmaceuticals (NASDAQ:ZNTL) had its price target cut by analysts at Wells Fargo & Company from $8.00 to $6.00 in a research note issued to investors on Thursday,Benzinga reports. The brokerage currently has an “equal weight” rating on the stock. Wells Fargo & Company‘s target price suggests a potential upside of 261.45% from the stock’s current price.

A number of other analysts have also recently commented on ZNTL. Wedbush reaffirmed a “neutral” rating and set a $4.00 target price on shares of Zentalis Pharmaceuticals in a report on Friday, January 24th. Guggenheim cut their target price on shares of Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating for the company in a research note on Friday, November 15th. HC Wainwright cut their target price on shares of Zentalis Pharmaceuticals from $20.00 to $10.00 and set a “buy” rating for the company in a research note on Wednesday. Finally, UBS Group cut their target price on shares of Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating for the company in a research note on Tuesday. Five investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, Zentalis Pharmaceuticals presently has an average rating of “Hold” and a consensus price target of $8.24.

Zentalis Pharmaceuticals Price Performance

Zentalis Pharmaceuticals stock traded down $0.23 during midday trading on Thursday, reaching $1.66. 3,656,997 shares of the company traded hands, compared to its average volume of 2,910,479. The firm has a market capitalization of $118.29 million, a price-to-earnings ratio of -0.67 and a beta of 1.86. The business has a 50 day moving average of $3.00 and a two-hundred day moving average of $3.30. Zentalis Pharmaceuticals has a 12 month low of $1.66 and a 12 month high of $18.07.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.56) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.36. As a group, equities analysts forecast that Zentalis Pharmaceuticals will post -2.48 EPS for the current year.

Hedge Funds Weigh In On Zentalis Pharmaceuticals

Several large investors have recently made changes to their positions in the company. Barclays PLC increased its holdings in Zentalis Pharmaceuticals by 18.5% in the 3rd quarter. Barclays PLC now owns 75,395 shares of the company’s stock worth $277,000 after acquiring an additional 11,748 shares in the last quarter. GSA Capital Partners LLP increased its position in Zentalis Pharmaceuticals by 138.5% during the third quarter. GSA Capital Partners LLP now owns 608,585 shares of the company’s stock worth $2,240,000 after purchasing an additional 353,384 shares during the last quarter. Verition Fund Management LLC increased its position in Zentalis Pharmaceuticals by 172.1% during the third quarter. Verition Fund Management LLC now owns 1,504,320 shares of the company’s stock worth $5,536,000 after purchasing an additional 951,500 shares during the last quarter. Primecap Management Co. CA increased its position in Zentalis Pharmaceuticals by 21.6% during the third quarter. Primecap Management Co. CA now owns 1,498,030 shares of the company’s stock worth $5,513,000 after purchasing an additional 265,690 shares during the last quarter. Finally, Algert Global LLC acquired a new stake in Zentalis Pharmaceuticals during the second quarter worth about $78,000.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.